Procalcitonin Antibody Market - Size, Share, Outlook, and Forecast till 2026

Procalcitonin (PCT) is a peptide precursor of 116 amino acids produced by parafollicular cells of the thyroid and neuroendocrine cells of lungs and intestine. It is used for synthesis of hormone calcitonin, which is involved in calcium homeostasis. The level of procalcitonin in blood increases as response to bacterial infection. The level of procalcitonin in the blood stream of healthy individuals is below the limit of detection (0.01 µg/L) of clinical assays. Procalcitonin antibodies are used as biomarker that exhibits greater specificity than proinflammatory markers (e.g. cytokines) for diagnosis of patients with sepsis and bacterial infections.

Get Sample copy of research report: https://www.worldwidemarketreports.com/sample/196815

Increasing adoption of procalcitonin antibody for diagnosis of sepsis and other associated disorders is major factor fueling growth of the procalcitonin antibody market. Bacterial or microbial infections results into development of sepsis, which requires effective treatment and prognostic assessment. Conventional clinical laboratory methods for diagnosis of bacterial infections are either non-specific or require longer turnaround times, which is propelling demand for procalcitonin antibodies as biomarker to detect formation of sepsis. Furthermore, procalcitonin antibodies are used for carrying out various research tests such as ELISA, Immunocytochemistry/Immunofluorescence, Immunohistochemistry, Sandwich ELISA, and Western Blot, which is driving growth of the procalcitonin antibody market.

Get Best Discount on Research Report: https://www.worldwidemarketreports.com/discount/196815

Key Developments of Procalcitonin Antibody Market

Market players offer procalcitonin antibodies for wide variety of applications in order to meet increasing demand from diagnostic centers and research and development industry. In February 2017, the US Food and Drug Administration (FDA) approved use of a rapid procalcitonin test to determine if antibiotics should be started or stopped in patients with lower respiratory tract infections, such as community-acquired pneumonia and stopped in patients with sepsis. Furthermore, according to the new findings published in Critical Care Medicine, procalcitonin is an effective biomarker for infection and it can be used to determine antibiotic discontinuation in patients with suspected or confirmed sepsis, without causing adverse effects on outcomes.

Market players are engaged in developing novel diagnostics kits in order to maintain leading position in procalcitonin antibody market. In June 2018, Fujirebio Diagnostics received Food and Drug Administration (FDA) clearance for a new procalcitonin assay to be used on its Lumipulse G1200 immunoassay platform.Key players operating in procalcitonin antibody market include Thermo Fisher, Roche Diagnostics, bioMerieux, HyTest, Wondfo, Ningbo Medicalsystem Biotechnology, Snibe, Vazyme Biotech, Getein Biotech, and Hotgen Biotech.

About WMR
Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:
Mr. Shah
Worldwide Market Reports
1001 4th Ave,
#3200
Seattle, WA 98154,
U.S
Tel: +1 415 871 0703

This release was published on openPR.